P-D-R Pharma Documentation Ring

The P-D-R is an association whose members represent the scientific information departments of the leading international R&D-based pharmaceutical corporations.

Latest News from the P-D-R Company Websites

Published 18 July 2018 | 8:00 pm

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- more ...

Published 18 July 2018 | 6:59 pm

Press Release Archives

Pfizer and Lilly Announce Positive Top-Line Results from Phase 3 Trial of Tanezumab for the Treatment of Osteoarthritis (OA) Pain more ...

Published 18 July 2018 | 6:37 pm

ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including more ...

Published 18 July 2018 | 2:25 pm

Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)

Broad clinical program to include three studies expected to begin in the third quarter of calendar year 2018 in addition to the now fully enrolled Phase 1b/2a trial of adults with more ...

Published 18 July 2018 | 12:51 pm

Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain

Pfizer Inc.(NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous more ...

Published 18 July 2018 | 8:03 am

Takeda Submits an Application for a New Indication of Entyvio (vedolizumab) for the Treatment of Adult Patients with Moderately to Severely Active Crohn's Disease in Japan

- Offers Potential New Treatment Option for Patients with Crohn's Disease more ...

Published 18 July 2018 | 7:22 am

Novartis Financial Results - Q2 2018

Today, Novartis announced the company's financial results for the second quarter and H1 of 2018. more ...

Published 18 July 2018 | 7:22 am

Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU more ...

Published 18 July 2018 | 7:01 am

Media Release

FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) more ...

Published 17 July 2018 | 5:41 pm

Investor Update

Chugai to In-license ROS1/TRK Inhibitor Entrectinib more ...

Pharma Documentation Ring:
26 companies - 4 common aims:

  • Promote exchange of experience/networking among members
  • Encourage commercial development of new information services and systems
  • Jointly assess new and existing products and services
  • Provide a forum for the information industry
  • How to become a P-D-R member?
Next Annual General Meeting, Vienna, September 25 – 28, 2018

Next Annual General Meeting, Vienna, September 25 – 28, 2018